Efficacy of intranasal fluticasone propionate nano nasal spray in management of chronic rhinitis: a randomized clinical trial

Common inflammatory conditions of the airways, such as chronic rhinitis, nasal polyposis, seasonal and chronic allergic rhinitis can greatly affect a patient’s health and quality of life. For each of these disorders, intranasal corticosteroids are suggested as a component of the therapy regimen because they can assist to lessen symptoms by reducing inflammation. In this randomized controlled trial, 30 people with rhinitis were enrolled to evaluate a new nano formulation of fluticasone propionate nano-nasal spray (FP-NNS) with commercially available nasal spray called FP-NS for the treatment of allergic rhinitis (15 to 60 years). 50 mcg dosages of FP-NNS were administered to patients in the morning and evening. This regimen was administered as a nasal spray for a 4-week effectiveness and safety phase. Analysis of variance was used to evaluate each efficacy endpoint. More of our clinical studies have shown that FP-NNS reduces inflammatory indicators in adults and children.